


Meet AZN Management: ESMO 2026

Investor Event – Faculty Biographies

26 October 2026



Pascal Soriot

Chief Executive Officer

Pascal is Executive Director and Chief Executive Officer at AstraZeneca. He has been a member of the Board and CEO since October 2012. Pascal has a passion for science and medicine as well as a successful track record of managing change, executing strategy and leading a diverse organisation.

Prior to AstraZeneca, Pascal served as COO of Roche's pharmaceuticals division from 2010 to 2012 and previously as CEO of Genentech where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior roles in numerous major companies around the world. He is a Doctor of Veterinary Medicine and holds an MBA from HEC Paris.

Pascal received a British knighthood for services to life sciences and leadership in the global response to the COVID pandemic in the Queen's Birthday Honours 2022. He is also on the board of the Sustainable Markets Initiative and champions the Health Systems Task Force which aims to accelerate the delivery of net zero, sustainable healthcare.



Dave Fredrickson

Executive Vice President, Oncology Haematology Business

Dave was appointed Executive Vice President, Oncology Haematology Business Unit in October 2017 and is responsible for driving growth and maximising the global commercial performance of the AstraZeneca global Oncology portfolio.

Previously, Dave served as President of AstraZeneca Japan and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association.

Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions. Prior to this, Dave worked at the Monitor Group, now Monitor Deloitte Group, a global strategy consultancy.

Dave is a graduate of Georgetown University in Washington DC.



Susan Galbraith

Executive Vice President, Oncology Haematology R&D

Susan was appointed as Executive Vice President, Oncology Haematology Research & Development in July 2021, with responsibility for transforming the productivity and scientific output from Oncology R&D. Over her career, Susan has helped develop >10 approved medicines.

As a clinical oncologist, Susan studied medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she has been awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research, is a Fellow of the Academy of Medical Sciences and was elected to the Academy of the American Association for Cancer Research.

Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021 to 2024, she also served on the Board of Directors of the AACR and currently serves on the European Association for Cancer Research Advisory Council.



Leora Horn

SVP, Late Development Oncology

As Senior Vice President of Late Development Oncology, Leora leads a global team dedicated to advancing innovative and novel therapies through late-stage clinical development and regulatory approval.

Prior to her current role, Leora served as Head of Clinical Development, Late Development Oncology, leading the development and resourcing for the physicians and scientists responsible for advancing studies from early signal-seeking to Phase III registrational trials spanning multiple indications. She also served as a Clinical Strategy Head for AstraZeneca's global research and development in lung cancer.

Leora previously worked at Vanderbilt-Ingram Cancer Center where she led the lung cancer program and participated as principal investigator on several national and global lung cancer trials and published over 175 papers and book chapters. Leora is an active member of, and has served on scientific committees for, the American Society of Clinical Oncology, the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.



Sunil Verma

Senior Vice President, Global Head, Oncology Franchise

Sunil Verma is Global Head, Oncology Franchise at AstraZeneca. His leadership is focused on advancing the commercial execution of the Company's transformative medicines in markets across the globe and leading the Oncology business unit strategy to help lead and build the next wave of the portfolio. Dr Verma is internationally recognised for his leadership in helping to transform the cancer paradigms with the development of pivotal medicines across multiple tumor types and settings.

Before joining AstraZeneca in August 2019, Dr Verma was a Medical Oncologist, providing clinical care and expertise with a focus on breast and lung cancer and held several pivotal leadership and research roles in academic medicine over 15 years. He served as Professor and Head of the Department of Oncology at the University of Calgary and the Medical Director of the Tom Baker Cancer Centre from 2015-2019. He also served on faculty at the University of Toronto as Associate Professor and Medical Director of the Breast Cancer Centre at Sunnybrook, Toronto.



Thomas Powles

Urology Medical Oncologist, University of London and Director of Barts Cancer Centre

Professor Thomas Powles is Chair of Barts Cancer Centre and leads both the Barts Health Experimental Cancer Medicine Centre and the Biomedical Research Centre.

He has held a range of global cancer roles, including Editor-in-Chief of *Annals of Oncology*, and has chaired a number of international guideline committees. He also holds honorary chairs in Europe and China.

His work has been recognised with several major cancer awards, including Nature's 10 and the TIME100 Health. His podcast, Uromigos, has had over 500,000 listens. He has played a leadership role at both the European Society for Medical Oncology and the American Society of Clinical Oncology meetings, and has contributed to 15 drug and biomarker approvals by the European Medicines Agency and the US Food and Drug Administration.



Yi-Long Wu

Professor of Lung Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital

Prof. Yi-Long Wu is a tenured professor at Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung Cancer Institute. He is the Past President of the Chinese Society of Clinical Oncology and President of the Chinese Thoracic Oncology Group. He has served on the Board of Directors and Staging Committee of the International Association for the Study of Lung Cancer (IASLC), chaired the 2020 World Conference on Lung Cancer and continues to chair the Joint IASLC–CSCO–CAALC Session at WCLC.

His research focuses on multidisciplinary and translational lung cancer treatment and evidence-based oncology. He has led more than 100 multicentre clinical trials and published over 500 peer-reviewed articles, including in the *New England Journal of Medicine*, *The Lancet, Nature Medicine* and *Journal of Clinical Oncology*. His work has helped advance adjuvant targeted therapy in non-small-cell lung cancer, including ALINA, ADAURA, LIBRETTO-431, CTONG1104 and CTONG1103.